Peptides, Patients And The FDA: The Full AAPM Press Briefing
Hearings & news coverage — Peptides, Patients And The FDA: The Full AAPM Press Briefing
Channel: American Academy of Peptide Medicine · Our label: Hearing coverage and news reporting · Source: youtube.com/watch?v=LJRUzT1f2o4
What this video covers
Good afternoon everyone and thank you for joining us. I’m Sarah Tatri, chief operating officer of the American Academy of Peptide Medicine. On behalf of AAPM, I want to welcome you to today’s briefing. We have a tremendous lineup of speakers with us today, physicians, researchers, and leaders who will speak to the science, the patient impact, and the path forward for safe, regulated peptide therapies.
Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.
Key points, in the speaker’s own framing
- pre-clinical work across multiple organ systems, human studies on tissue repair, gastrointestinal protection, pain.
- and I now educate physicians from around the world in the safe and effective use of these prescribed and compounded peptide therapies.
- On July 23rd and 24th the FDA will decide whether physicians like me can keep prescribing these peptides through licensed safe compoundingies.
- What we do know about the risk of a peptide made by a licensed pharmacy prescribed by a doctor against the total unknown of a vial with no label that someone bought online.
- So we asked a simple question based on what evidence, what data, what studies, where was the proof that these peptides posed the danger the agency claimed?
- And when you compare that to those that are already FDA approved, which includes insulin, vasopressin smatotropen growth hormone, GLP1s and many others, it is drastically drastically lower.
Read next
Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.